The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The decision made in the year 2004 by the U.S. Food and Drug Administration (FDA) to require a boxed warning on antidepressants regarding the risk of suicidality in young adults still represents a matter of controversy. The FDA warning was grounded on industry-sponsored trials carried one decade ago or earlier. However, within the past decade, an increasing number of reports have questioned the actual validity of the FDA warning, especially considering a decline in the prescription of the antidepressant drugs associated with an increase in the rate of suicidal events among people with severe depression. The present report provides an overview of the FDA black box warning, also documenting two Major Depressive Disorder patients whose refusal to undergo a pharmacological antidepressant treatment possibly led to an increased risk for suicidal behaviors. The concerns raised by the FDA black box warning need to be considered in real-world clinical practice, stating the associated clinical and public health implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Hirschfeld, R. M. A., Williams, J. B. W., Spitzer, R. L., Calabrese, J. R., Flynn, L., Keck, P. E., Lewis, L., McElroy, S. L., Post, R. M., Rapport, D. J., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1873 · Cited by 1,525
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020185 · Cited by 770
Suicide Risk During Antidepressant Treatment
Simon, G. E., Savarino, J., Operskalski, B., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.41 · Cited by 424 · cited 1×
“However, the corresponding evidence for MDD is not that compelling, especially beyond the acute treatment phase of unipolar depression (9).”
BackgroundValuck, R. J., Libby, A. M., Sills, M. R., Giese, A. A., & Allen, R. R. (2004) · CNS Drugs · doi:10.2165/00023210-200418150-00006 · Cited by 182
Antidepressants' Black-Box Warning — 10 Years Later
Friedman, R. A. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1408480 · Cited by 171 · cited 1×
“As pointed out by Friedman (52), the FDA was aware of the need to balance the quantitatively small risk associated with antidepressant treatment against related proven benefits, yet it expanded the black-box warning issued in 2007 stating that depression itself is associated with an increased risk of suicide (52).”
BackgroundGibbons, R. D., Brown, C. H., Hur, K., Marcus, S. M., Bhaumik, D. K., & Mann, J. J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1044 · Cited by 167
Fornaro, M., Anastasia, A., Novello, S., Fusco, A., Solmi, M., Monaco, F., Veronese, N., De Berardis, D., & de Bartolomeis, A. (2018) · Bipolar Disorders · doi:10.1111/bdi.12612 · Cited by 93
Self-citationFornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., Solmi, M., Veronese, N., Stubbs, B., Vieta, E., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.025 · Cited by 80
Self-citation
Cited by
Understanding the Complex of Suicide in Depression: from Research to Clinics
Orsolini, L., Latini, R., Pompili, M., Serafini, G., Volpe, U., Vellante, F., Fornaro, M., Valchera, A., Tomasetti, C., Fraticelli, S., et al. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0171 · Cited by 406
Self-citationSolmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Self-citationVan Meter, A. R., Knowles, E. A., & Mintz, E. H. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.07.867 · Cited by 193
Suicide in Northern Ireland: epidemiology, risk factors, and prevention
O'Neill, S., & O'Connor, R. C. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30525-5 · Cited by 67
Inpatient suicide in psychiatric settings: Evaluation of current prevention measures
Chammas, F., Januel, D., & Bouaziz, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.997974 · Cited by 38
Pharmacologic approaches to suicide prevention
Zisook, S., Domingues, I., & Compton, J. (2023) · Focus · doi:10.1176/appi.focus.20220076 · Cited by 30
van der Spek, N., Dekker, W., Peen, J., Santens, T., Cuijpers, P., Bosmans, G., & Dekker, J. (2024) · Crisis · doi:10.1027/0227-5910/a000916 · Cited by 13
Bockting, C., Bosmans, G., Bergers, N., Gavan, L., Hiligsmann, M., de Beurs, D., Molenberghs, G., Wijnen, B., Lokkerbol, J., & van der Spek, N. (2024) · Trials · doi:10.1186/s13063-024-08499-7 · Cited by 1
Metadata
- Authors
- Fornaro, M., Anastasia, A., Valchera, A., Carano, A., Orsolini, L., Vellante, F., Rapini, G., Olivieri, L., Di Natale, S., Perna, G., Martinotti, G., Di Giannantonio, M., & De Berardis, D.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2019-05-03
- Volume
- 10
- Pages
- 294-294
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2942916479
- Cited by
- 99
- References
- 10
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.